Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions necessary for nerve conduction, muscle contraction, and maintenance of intracellular tonicity. Dextrose 5% provides a source of calories and is metabolized to carbon dioxide and water, supplying energy. Sodium chloride provides sodium and chloride ions for electrolyte balance and maintenance of osmotic pressure.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Fluid and electrolyte replenishment to correct or prevent dehydration and electrolyte imbalances,Hypokalemia (low potassium) prevention or treatment,Maintenance of intravenous nutrition
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion at a rate not exceeding 10-20 m Eq/hour of potassium; typical dose for hypokalemia: 20-40 m Eq potassium chloride per liter of IV fluid, infused at a rate to correct deficit. Actual dose depends on serum potassium level and clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Not applicable for combined electrolyte/caloric solution; potassium distribution half-life ~1-1.5 hours; for potassium, elimination half-life depends on renal function (normal: ~6-8 hours, anuria: prolonged).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Potassium: not metabolized, excreted primarily by kidneys. Dextrose: undergoes glycolysis and enters Krebs cycle. Sodium chloride: not metabolized, excreted by kidneys.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: >90% of potassium ion excreted by kidneys (distal tubular secretion and reabsorption); <10% fecal (via gastrointestinal secretion). Dextrose and sodium chloride components are fully metabolized or excreted renally.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Potassium: minimal (<5%, not bound to proteins). Dextrose and sodium: not bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Potassium: total body water (0.5-0.6 L/kg); distribution includes intracellular space (98% of total body potassium is intracellular).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
IV: 100% (complete bioavailability). No oral route for this product.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia; use with caution in mild to moderate impairment with frequent potassium monitoring. Reduce dose or prolong infusion time based on serum potassium levels.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment required for hepatic impairment; monitor serum potassium as hepatic dysfunction can affect acid-base balance and potassium distribution.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Dose individualized based on weight, serum potassium, and clinical condition. Typical initial infusion rate: 0.2-0.5 m Eq/kg/hour; maximum rate: 1 m Eq/kg/hour under continuous ECG monitoring. Maximum daily dose: 3 m Eq/kg/day.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use with caution due to age-related decline in renal function; start at lower end of dosing range and titrate based on serum potassium and renal function. Monitor for hyperkalemia, especially in those with impaired renal function or on ACE inhibitors/ARBs.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warning for this specific combination product. However, potassium chloride can cause fatal hyperkalemia if administered in excess or too rapidly.
None
Risk of hyperkalemia, especially in patients with renal impairment, heart disease, or on potassium-sparing diuretics,Monitor serum potassium, glucose, and electrolytes during prolonged therapy,Administration via peripheral line may cause phlebitis; central line preferred for concentrated solutions,Use with caution in patients with cardiac arrhythmias, renal failure, or adrenal insufficiency
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperkalemia,Renal failure with oliguria or anuria,Addison's disease (adrenal insufficiency),Acute dehydration,Heat cramps,Patients with severe cardiac disease or heart block,Concurrent use of potassium-sparing diuretics or ACE inhibitors without careful monitoring
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No direct food interactions. However, consider the patient's overall electrolyte and fluid balance from dietary intake; avoid high-potassium foods if hyperkalemia is a concern.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Potassium chloride and dextrose are not associated with teratogenicity at usual therapeutic doses. Sodium chloride in typical amounts is not teratogenic. First trimester exposure considered low risk. Second and third trimesters: no known fetal harm. However, maternal electrolyte disturbances (e.g., hyperkalemia, hypernatremia) can affect fetal homeostasis.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Potassium and chloride are normal milk constituents; dextrose is a normal sugar. Exogenous administration does not significantly alter breast milk composition. M/P ratio not established; considered compatible with breastfeeding with usual doses. Monitor for infant electrolyte imbalance if high doses administered.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy increases plasma volume and glomerular filtration rate, potentially accelerating potassium and fluid clearance. No standard dose adjustment, but careful monitoring of electrolytes and fluid status is recommended. Dextrose may require adjustment in gestational diabetes.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This solution is isotonic (approximately 263 m Osm/L) and provides maintenance fluids with potassium. Do not administer undiluted; ensure patency of IV line. Monitor serum potassium and renal function, especially in patients with renal impairment, cardiac disease, or during rapid infusions. Use with caution in patients receiving potassium-sparing diuretics. Incompatible with amphotericin B and erythromycin.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This intravenous solution contains potassium, dextrose, and sodium chloride.,Report any pain, redness, or swelling at the IV site.,Tell your doctor if you have kidney problems, heart disease, or are taking any medications.,This is for intravenous use only; do not drink or inject at home.,You may experience a metallic taste or flushing if the infusion is too rapid.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions necessary for nerve conduction, muscle contraction, and maintenance of intracellular tonicity. Dextrose 5% provides a source of calories and is metabolized to carbon dioxide and water, supplying energy. Sodium chloride provides sodium and chloride ions for electrolyte balance and maintenance of osmotic pressure.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10-20 m Eq/hour of potassium; typical dose for hypokalemia: 20-40 m Eq potassium chloride per liter of IV fluid, infused at a rate to correct deficit. Actual dose depends on serum potassium level and clinical status.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride and dextrose are not associated with teratogenicity at usual therapeutic doses. Sodium chloride in typical amounts is not teratogenic. First trimester exposure c. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.